Bibliographic Details
| Title: |
The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. |
| Authors: |
Stotz, Michael, Barth, Dominik A., Riedl, Jakob M., Asamer, Eva, Klocker, Eva V., Kornprat, Peter, Hutterer, Georg C., Prinz, Felix, Lackner, Karoline, Stöger, Herbert, Gerger, Armin, Pichler, Martin |
| Source: |
Cancers; Jul2020, Vol. 12 Issue 7, p1798, 1p |
| Subject Terms: |
AGE distribution, AMYLASES, CANCER chemotherapy, CANCER patients, CONFIDENCE intervals, LIPASES, METASTASIS, MULTIVARIATE analysis, PANCREATIC tumors, PATIENTS, SEX distribution, STATISTICS, SURGERY, SURVIVAL analysis (Biometry), TUMOR markers, PROPORTIONAL hazards models, RETROSPECTIVE studies, DUCTAL carcinoma, DESCRIPTIVE statistics, KAPLAN-Meier estimator, KARNOFSKY Performance Status |
| Abstract: |
Pancreatic enzymes might play a pivotal role in the pathophysiology and prognosis of pancreatic cancer. The aim of this study is to investigate the lipase/amylase ratio (LAR), representing a marker previously used in the differentiation of pancreatitis, as a potential prognostic marker in pancreatic cancer. Data from 157 surgically treated patients with ductal pancreatic adenocarcinoma and 351 patients with metastatic disease were evaluated retrospectively. Cancer-specific survival (CSS) was considered the endpoint of the study. After applying Kaplan–Meier curve analysis, uni- and multivariate Cox regression models were calculated to evaluate the prognostic relevance of LAR. An elevated LAR at diagnosis of localized pancreatic cancer was significantly associated with higher CA19-9 levels (p < 0.05). In univariate analysis, we observed an increased LAR as a significant factor for lower CSS in localized pancreatic cancer patients (HR = 1.63; 95% CI = 1.12–2.36; p = 0.01), but not in metastatic patients (HR = 1.12; 95% CI = 0.87–1.43; p = 0.363). In multivariate analysis, including age, gender, tumor stage, Karnofsky Performance Status, tumor grade, administration of chemotherapy and the LAR, an increased LAR was confirmed to represent an independent prognostic factor regarding CSS (HR = 1.81; 95% CI = 1.17–2.77; p = 0.007) in localized pancreatic cancer patients. In conclusion, our study identified the LAR as an independent prognostic factor in surgically treated pancreatic cancer patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
